Holen Sie sich die Stockscreener-App
8.635
2.65%
-0.235
Schlusskurs vom Vortag:
$8.87
Offen:
$8.92
24-Stunden-Volumen:
1.77M
Relative Volume:
0.29
Marktkapitalisierung:
$1.88B
Einnahmen:
$51.95M
Nettoeinkommen (Verlust:
$-265.94M
KGV:
-6.0032
EPS:
-1.4384
Netto-Cashflow:
$-216.89M
1W Leistung:
-15.92%
1M Leistung:
-2.76%
6M Leistung:
-32.59%
1J Leistung:
+9.58%
1-Tages-Spanne:
$8.50
$9.03
1-Wochen-Bereich:
$8.50
$10.25
52-Wochen-Spanne:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.635 | 1.93B | 51.95M | -265.94M | -216.89M | -1.4384 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - The Globe and Mail
Ocular Therapeutix at The Citizens Life Sciences Conference: AXPAXLI’s Promising Results - Investing.com Canada
OCUL: AXPAXLI's phase III success sets a new standard in wet AMD, with regulatory approval in progress - TradingView
Ocular Therapeutix Opens with 8.61% Gain Amid Ongoing Financial Challenges - Markets Mojo
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rhenman & Partners Asset Management AB Buys Shares of 202,000 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Can Ocular Therapeutix Inc. stock surprise with earnings upsideJuly 2025 Intraday Action & Technical Buy Zone Confirmation - Naître et grandir
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Ocular Therapeutix (OCUL) Is Up 16.2% After Detailing Retinal Pipeline Progress And Upcoming Milestones - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Bought by Vanguard Group Inc. - MarketBeat
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation - simplywall.st
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Stea - GuruFocus
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Grows By 27.8% - MarketBeat
William Blair Maintains Outperform on Ocular Therapeutix, Inc. (OCUL) March 2026 - Meyka
Ocular Therapeutix Breaks Above 200-Day Moving AverageBullish for OCUL - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 17.4%Should You Buy? - MarketBeat
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix at TD Cowen Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Canada
OCUL: Superiority achieved in retina study, paving way for broad label and premium market position - TradingView
Ocular Therapeutix Director Pravin Dugel Sells Shares - TradingView
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations - Yahoo Finance
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Yahoo Finance
Ocular Therapeutix Shares Fall After Inflation Report | 2026 Market UpdateNews and Statistics - IndexBox
Ocular Therapeutix (NASDAQ:OCUL) Cut to Sell at Wall Street Zen - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflecting Its Recent Volatility And DCF Implied Upside - simplywall.st
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why - Yahoo Finance
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress - TipRanks
Ocular Therapeutix to Release SOL-1 Phase 3 AXPAXLI Trial Slides at Macula Society Meeting - TradingView
Ocular Therapeutix chief development officer Kaiser sells $23k in stock - Investing.com India
Sanjay Nayak Sells 1,759 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Peter Kaiser Sells 2,810 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $166,063.68 in Stock - MarketBeat
Ocular Therapeutix, Inc. (OCUL) Investor Outlook: A Biotech With A 205% Potential Upside - DirectorsTalk Interviews
Ocular Therapeutix (NASDAQ:OCUL) Insider Nadia Waheed Sells 3,510 Shares - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Director Richard Md Lindstrom Acquires 60,229 Shares - MarketBeat
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock By Investing.com - Investing.com Canada
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock - Investing.com South Africa
Ocular Therapeutix Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Ocular Therapeutix to Participate in March Investor Conferences - Bitget
Ocular Therapeutix™ to Participate in March Investor Conferences - The Manila Times
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):